A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Kandalaft, Lana E ^a   Powell Jr, Daniel J ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; FOLATE RECEPTOR 1; MEMBRANE ANTIGEN;

ADOPTIVE TRANSFER; ADULT; ARTICLE; CANCER STAGING; CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; LYMPHOCYTE DEPLETION; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; SAFETY; T LYMPHOCYTE; IMMUNOLOGY; METABOLISM; OVARY TUMOR; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RECURRENT DISEASE;

ADOPTIVE TRANSFER; FEASIBILITY STUDIES; FEMALE; FOLATE RECEPTOR 1; HUMANS; OVARIAN NEOPLASMS; RECURRENCE; T-LYMPHOCYTES;

EID: 84864518399     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-157     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol 2007, 34:S1-S15.
3. Morgan RJ, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Johnston C, Lancaster JM, Lele S, Matulonis U, Ozols RF, Remmenga SW, Sabbatini P, Soper J, Teng N. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4:912-939.
4. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006, 17(Suppl 5):v181-v187.
5. Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008, 8:243-257. 10.1586/14737140.8.2.243, 18279065.
6. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007, 117:1466-1476. 10.1172/JCI32446, 1878537, 17549249.
7. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1995, 1:501-507.
8. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991, 51:1934-1939.
9. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007, 117:1204-1212. 10.1172/JCI31446, 1857246, 17476350.
10. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997, 185:833-841. 10.1084/jem.185.5.833, 2196170, 9120389.
11. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003, 111:639-647. 151894, 12618518.
12. Kessels HW, Wolkers MC, Schumacher TN. Adoptive transfer of T-cell immunity. Trends Immunol 2002, 23:264-269. 10.1016/S1471-4906(02)02219-6, 12102748.
13. Clay TM, Morse M, Lyerly HK. Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. Expert Opin Biol Ther 2002, 2:353-360. 10.1517/14712598.2.4.353, 11955274.
14. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45. 10.1038/nrc971, 12509765.
15. Gabert J, Langlet C, Zamoyska R, Parnes JR, Schmitt-Verhulst AM, Malissen B. Reconstitution of MHC class I specificity by transfer of the T cell receptor and Lyt-2 genes. Cell 1987, 50:545-554. 10.1016/0092-8674(87)90027-4, 2955903.
16. Saito T, Weiss A, Miller J, Norcross MA, Germain RN. Specific antigen-Ia activation of transfected human T cells expressing murine Ti alpha beta-human T3 receptor complexes. Nature 1987, 325:125-130. 10.1038/325125a0, 3027582.
17. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989, 86:10024-10028. 10.1073/pnas.86.24.10024, 298636, 2513569.
18. Mullaney BP, Pallavicini MG. Protein-protein interactions in hematology and phage display. Exp Hematol 2001, 29:1136-1146. 10.1016/S0301-472X(01)00693-2, 11602315.
19. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270. 10.1038/nm.1882, 2749734, 18978797.
20. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056. 10.1182/blood-2011-05-354449, 21984804.
21. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73. 10.1126/scitranslmed.3002842, 3393096, 21832238.
22. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733. 10.1056/NEJMoa1103849, 3387277, 21830940.
23. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828. 10.1182/blood-2011-04-348540, 21849486.
24. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720. 10.1182/blood-2011-10-384388, 22160384.
25. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102. 10.1182/blood-2010-04-281931, 2993617, 20668228.
26. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12:6106-6115. 10.1158/1078-0432.CCR-06-1183, 2154351, 17062687.
27. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 1991, 88:5572-5576. 10.1073/pnas.88.13.5572, 51919, 2062838.
28. Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, Zurawski VR. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991, 51:6125-6132.
29. Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug 1998, 15:587-627.
30. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem 2010, 53:6811-6824. 10.1021/jm100509v, 20666486.
31. Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009, 49:1467-1476. 10.1177/0091270009339740, 19837906.
32. Sausville EA, LoRusso P, Quinn M, Forman K, Leamon CP, Morgenstern D, Bever S, Messmann RA. A Phase I Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Patients with Refractory Solid Tumors 2007, 2577. , Alexandria, VA.
33. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010, 16:5288-5295. 10.1158/1078-0432.CCR-10-0700, 20855460.
34. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AM, Goey SH, Gratama JW, Lamers CH, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995, 87:1463-1469. 10.1093/jnci/87.19.1463, 7674333.
35. Song DD, Carpenitow C, Poussin M, Canevari S, June CH, Coukos G, Powell DJ. Improved Persistence and In Vivo Antitumor Efficacy of Human T Cells Engineered to Express a 4-1BB Costimulated Alpha-Folate Receptor-Specific Chimeric Immune Receptor. Journal of Immunotherapy 2010, 33:865-865.
36. Powell DJ, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy 2009, 11:923-935. 10.3109/14653240903188921, 19903104.
37. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624, 19934295.
38. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004, 173:7125-7130. 2175171, 15585832.
39. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005, 202:907-912. 10.1084/jem.20050732, 1397916,1397916, 16203864.
40. Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol 2000, 1:426-432. 10.1038/80868, 11062503.
41. Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Schwartzentruber DJ. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996, 2:263-272.
42. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851. 10.1038/mt.2010.24, 2862534, 20179677.
43. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010, 18:666-668. 10.1038/mt.2010.31, 2862525, 20357779.
44. Lamers CH SS, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. Clin Oncol 2006, 24:e20-e22.
45. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213. 10.1056/NEJMoa020177, 12529460.
46. Kandalaft LE, Powell DJ. Singh N, Coukos G: Immunotherapy for ovarian cancer: what's next?. J Clin Oncol 2011, 29:925-933. 10.1200/JCO.2009.27.2369, 3068064, 21079136.
47. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489. 10.1038/nature10673, 22193102.
48. Fruci D, Benevolo M, Cifaldi L, Lorenzi S, Lo Monaco E, Tremante E, Giacomini P. Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. Curr Oncol 2012, 19:39-41. 3267590, 22328841.
49. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Kamen BA. Distribution of the Folate Receptor Gp38 in Normal and Malignant-Cell Lines and Tissues. Cancer Res 1992, 52:3396-3401.
50. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS, Ntziachristos V. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011, 17:1315-1319. 10.1038/nm.2472, 21926976.
51. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005, 26:111-117. 10.1016/j.it.2004.12.003, 1388277, 15668127.
52. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng Z, Westphal S, Mair R, Chi N, Ratterree B, Pochran MF, Natt S, Hinkle J, Sickles C, Sohal A, Ruehle K, Lynch C, Zhang L, Porter DL, Luger S, Guo C, Fang HB, Blackwelder W, Hankey K, Mann D, Edelman R, Frasch C, Levine BL, Cross A, June CH. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005, 11:1230-1237. 10.1038/nm1310, 16227990.
53. Rapoport AP, Grupp SA, Stadtmauer EA, Vonderheide RH, Levine BL, Fang HB, Yager K, Chew A, Veloso E, June CH. Rapid T cell recovery and possible auto-GVHD following adoptive transfer of ex-vivo costimulated autologous T cells at day+2 post transplant. Blood 2007, 110:236A-236A.
54. Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer 2011, 2:331-332. 3119397, 21716851.
55. Oei AL, Sweep FC, Geurts-Moespot A, van Tienoven D, Von Mensdorff-Pouilly S, Thomas CM, Massuger LF. Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1. Anticancer Res 2008, 28:2721-2725.